AdagrasibasibpembrolizumabsotorasibBI-2493G12CidocetaxeldaraxonrasibAZD4785RMC-7977
…d OS of 13.4 months,38 39 leading to full FDA approval in 2024. Adagrasib has also shown modest activity in PDAC (ORR 33%, PFS 5.4 months…
4articles mentioning drugs
15drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: adagrasib ×
adagrasib
This drug is selected. Its supporting articles are shown below.
Articles mentioning adagrasib
4 articles · page 1 of 1osimertinibcrizotinibsotorasibatezolizumabdurvalumablorlatinibosimertinib-treated
…ring may help identify patients who could benefit from extended osimertinib therapy, although further clinical validation is warranted.ctDN…
pembrolizumab5-fluorouracilleucovorinadagrasibzenocutuzumabliposomal irinotecandaraxonrasibPancreatic ductal adenocarcinoma (PDAC)NAPOLI-1 trialconventional chemotherapy
…d over 50% with RET or NTRK inhibitors with fusion alterations; pembrolizumab produces durable benefit in the 1–3% of tumours that are MSI-H/…
MRTX1257MRTX849AMG510adagrasibsotorasibMC38 colon cancerKRASG12C Lewis lung cancerKRASG12C cancer
…tors for KRAS G12C, AMG510 (sotorasib), MRTX849 (adagrasib) and MRTX1257, all displayed potent cytotoxicity to cancer cells harboring KR…